Eli Lilly licenses Adimab antibody discovery and optimization tech

By Melissa Fassbender contact

- Last updated on GMT

Adimab is a Lebanon, NH-based antibody discovery technology provider. (Image: iStock/Svisio)
Adimab is a Lebanon, NH-based antibody discovery technology provider. (Image: iStock/Svisio)

Related tags: Corporation, Eli lilly

Adimab, LLC is transferring its proprietary antibody discovery and optimization platform to Lilly research sites in San Diego and New York.

According to the company, the technology transfer expands an ongoing collaboration with Eli Lilly and Company, which was established in 2010.

As part of the agreement, Lilly will receive an exclusive, custom human antibody library, as well as a license to use the Adimab Platform in all therapeutic areas – without target restriction.

Additionally, Lilly has secured options to receive continued improvements to the Adimab Platform, including access to new antibody libraries.

Adimab will receive an undisclosed upfront fee and future payments dependent on achieving set preclinical and clinical milestones. The company will also receive royalties on any therapeutic products that result from the technology’s use.

Partnership activity

Adimab has established partnerships with 50 pharmaceutical and biotechnology companies over the past eight years and has also transferred and implemented its technology at Merck, Novo Nordisk, Biogen, and GSK. 

According to the company's mid-year partnership activity update, its most advanced program with partner Arsanis is currently in Ph II clinical trials.

New alliances this year include Anokion, Moderna Therapeutics, Mapp Biopharmaceutical, and Pionyr Immunotherapeutics, among others.

Related news

Show more

Related products

show more

Has EDC Kept Up With Changes In Clinical Trials?

Has EDC Kept Up With Changes In Clinical Trials?

Oracle Health Sciences | 14-Dec-2020 | Technical / White Paper

In just a few decades, clinical trials have changed dramatically. Twenty years ago, most of the data used in clinical research was entered on paper, but...

Liver Disease Capabilities

Liver Disease Capabilities

Q² Solutions | 01-Oct-2020 | Clinical Study

We integrate therapeutic insights, state-of-the-art technologies, best-in-class methods and quality systems to optimize NAFLD & NASH study design,...

CAR-T Cell Therapy

CAR-T Cell Therapy

Q² Solutions | 01-Sep-2020 | Clinical Study

Cell therapy involves the transfer of genetically altered cells into a patient. As a global central laboratory services organization, we provide testing...

Related suppliers

Follow us


View more